Navigation Links
KaloBios Pharmaceuticals, Inc. Prices Public Offering of Common Stock
Date:9/26/2013

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (KaloBios) (NASDAQ: KBIO) today announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a price to the public of $4.00 per share. The net offering proceeds to KaloBios are expected to be approximately $27,855,000 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the company, but excluding any exercise of the underwriters' over-allotment option.

(Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO)

KaloBios anticipates using the net proceeds from this offering to develop and advance its product candidates through clinical trials, as well as for working capital and other general corporate purposes. The offering is expected to close on or about October 1, 2013, subject to customary closing conditions. In addition, KaloBios has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock on the same terms and conditions, solely to cover over-allotments, if any.

Leerink Swann LLC is acting as the sole book-running manager for the offering.  William Blair & Company, L.L.C., Needham & Company LLC, and JMP Securities LLC are acting as co-managers for the offering.

The shares described above will be issued pursuant to a shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission (SEC) and a prospectus supplement thereto has been filed with the SEC. The offering may be made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained by sending a request to: Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or via telephone at (800) 808-7525. KaloBios intends to file a final prospectus supplement relating to the offering with the SEC, which will be available along with the accompanying prospectus filed with the SEC in connection with the shelf registration, on the SEC's website at www.sec.gov.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of KaloBios, nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is being issued pursuant to and in accordance with Rule 134 under the Securities Act of 1933, as amended.

About KaloBios Pharmaceuticals, Inc.

KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat severe medical conditions with a primary clinical focus on respiratory diseases and cancer. 

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements regarding the completion and timing of the public offering and expected use of proceeds from the public offering that involve risks and uncertainties, including, without limitation, risks related to the satisfaction of customary closing conditions. Such statements involve known and unknown risks that relate to future events or future financial performance and the actual results could differ materially from those discussed in this communication. There can be no assurance that KaloBios will be able to complete the public offering on the anticipated terms, or at all. Risks and uncertainties that may cause KaloBios's actual results to differ materially from those discussed in this communication can be found in the "Risk Factors" section of KaloBios's preliminary prospectus supplement related to the public offering filed with the SEC on September 23, 2013, and in the prospectus supplement related to the public offering that KaloBios expects to file with the SEC on or about September 26, 2013, and in its Form 10-K, Forms 10-Q and other filings with the SEC, each available at the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and KaloBios assumes no responsibility to update or revise any forward-looking statements contained in this communication to reflect events, trends or circumstances after the date of this communication.

Contact:

Jeffrey H. Cooper
Chief Financial Officer
KaloBios Pharmaceuticals, Inc.
(650) 243-3146
ir@kalobios.com

Media Contact:

Joan E. Kureczka
Kureczka/Martin Associates
Tel:  (415) 821-2413
Mobile: (415) 690-0210
Joan@Kureczka-Martin.com


'/>"/>
SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Herb C. Cross to Join KaloBios as Chief Financial Officer
2. KaloBios KB001 Anti-Pseudomonas Antibody Study Published in Pediatric Pulmonology
3. KaloBios to Present at Stifel Healthcare Conference 2013
4. KaloBios Reports First Quarter 2013 Financial Results
5. KaloBios to Present at Needham Healthcare Conference
6. KaloBios Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
7. KaloBios to Present at Future Leaders in the Biotech Industry Conference
8. Bioassociate Announces Initiation of Coverage on KaloBios Pharmaceuticals, Inc.
9. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma
10. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
11. KaloBios Pharmaceuticals Completes Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
Breaking Medicine News(10 mins):